Achilles Therapeutics plc

NasdaqCM ACHL

Achilles Therapeutics plc Price to Sales Ratio (P/S) on December 12, 2024

Achilles Therapeutics plc Price to Sales Ratio (P/S) is NA on December 12, 2024, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Achilles Therapeutics plc 52-week high Price to Sales Ratio (P/S) is NA on December 12, 2024, which is NA below the current Price to Sales Ratio (P/S).
Achilles Therapeutics plc 52-week low Price to Sales Ratio (P/S) is NA on December 12, 2024, which is NA below the current Price to Sales Ratio (P/S).
Achilles Therapeutics plc average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: ACHL

Achilles Therapeutics plc

CEO	Dr. Iraj Ali Ph.D.
IPO Date	March 31, 2021
Location	United Kingdom
Headquarters	245 Hammersmith Road
Employees	204
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years